Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

p53 Codon 72 Increased Biochemical Recurrence Risk after Radical Prostatectomy in a Southern Chinese Population

Xu B.a, b · Mi Y.-Y.a · Min Z.-C.a · Cheng G.a · Tong N.b · Tao J.a · Li P.-C.a · Wang M.-L.b · Tang J.-L.b · Zhang Z.-D.b · Song N.-H.a · Zhang W.a · Wu H.-F.a · Feng N.-H.a · Hua L.-X.a

Author affiliations

aDepartment of Urology, First Affiliated Hospital of Nanjing Medical University, and bDepartment of Molecular and Genetic Toxicology, Cancer Center of Nanjing Medical University, Nanjing, China

Related Articles for ""

Urol Int 2010;85:401–405

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 20, 2010
Accepted: May 29, 2010
Published online: July 20, 2010
Issue release date: December 2010

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 3

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN

Abstract

Introduction: Alterations in P53 and Murine Double Minute 2 (MDM2) genes appear to be important in the development of many human tumors. We investigated the potential prognostic roles of p53 codon 72 and MDM2 309 and 1797 polymorphisms in prostate cancer after radical prostatectomy. Patients and Methods: Fifty southern Chinese with prostate cancer undergoing radical prostatectomy were included in this study. All polymorphisms were detected by PCR-RFLP. Their prognosis on biochemical recurrence was assessed using Kaplan-Meier analysis and Cox regression model. Results:p53 codon 72 GG genotype was associated with increased biochemical recurrence compared with CG+CC genotypes and poorer PSA-free survival. It was also noted that GG genotype was an independent risk factor for biochemical recurrence after radical prostatectomy on multivariate analysis. No statistical difference was observed in MDM2 polymorphisms and prostate cancer prognosis. Conclusion: Our data revealed that p53 codon 72 GG genotype carriers more frequently show biochemical recurrence than CG+CC genotypes carriers.

© 2010 S. Karger AG, Basel


References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
    External Resources
  2. Gu F: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in china. Chin Med J (Engl) 2000;113:299–302.
  3. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555–565.
  4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–439.
  5. Hallstrom TM, Laiho M: Genetic changes and DNA damage responses in the prostate. Prostate 2008;68:902–918.
    External Resources
  6. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993;362:857–860.
  7. Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8: 162–200.
  8. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125–128.
  9. Huang SP, Huang CY, Wang JS, Liu CC, Pu YS, Yu HJ, et al: Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res 2007;13:6632–6638.
  10. Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, et al: Bcl2 -938c/a polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J Urol 2009;181:1907–1912.
  11. Bond GL, Hu W, Levine A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481–5484.
  12. Wang M, Zhang Z, Zhu H, Fu G, Wang S, Wu D, et al: A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a chinese population. Clin Cancer Res 2008;14:3633–3640.
  13. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, et al.: MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006;24:4434–4440.
  14. Jaboin JJ, Hwang M, Perez CA, Cooper C, Chen H, Ye C, et al: No evidence for association of the MDM2–309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol DOI: 10.1016/j.urolonc.2009.03. 031.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 20, 2010
Accepted: May 29, 2010
Published online: July 20, 2010
Issue release date: December 2010

Number of Print Pages: 5
Number of Figures: 1
Number of Tables: 3

ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)

For additional information: https://www.karger.com/UIN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.